Holocene Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Holocene Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-374,300	Closed	-$25.1M	–	988
2022 Q2	$25.1M	Hold	374,300	–	–	0.15%	172
2022 Q1	$30.8M	Buy	+374,300	New	+$38.3M	0.16%	158
2021 Q4	–	Sell	-348,800	Closed	-$61.7M	–	1011
2021 Q3	$61.7M	Buy	348,800 +17,500	+5%	+$2.82M	0.34%	98
2021 Q2	$53.5M	Buy	331,300 +91,300	+38%	+$14.7M	0.3%	116
2021 Q1	$41.1M	Buy	+240,000	New	+$47.5M	0.26%	121
2020 Q4	–	Sell	-115,000	Closed	-$19.1M	–	877
2020 Q3	$19.1M	Buy	+115,000	New	+$15.7M	0.15%	178

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Holocene Advisors's MRTX Position: Q2 2022 in Review

Holocene Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2022, closing a stake of 848,177 shares — an estimated $53.9M sold.

Holocene Advisors first reported a position in MRTX in Q3 2019 and held it in 11 quarters. The position peaked at $153M in Q4 2021. 230 funds tracked by Wall St. Rank hold MRTX as of Q2 2022.

Holocene Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Holocene Advisors sold 848,177 Mirati Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $53.9M.
Holocene Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and held it in 11 quarters.
Holocene Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $153M in Q4 2021.
230 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Holocene Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.